Posted by Michael Wonder on 04 Jul 2024
Hutchmed announces NDA acceptance in China for tazemetostat for the treatment of relapsed or refractory follicular lymphoma with priority review status
4 July 2024 - - Hutchmed (China) today announces that the new drug application for tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma has been accepted for review and granted priority review by the China National Medical Products Administration.
This China new drug application is supported by results from a multi-centre, open-label, Phase II bridging study in China, and clinical studies conducted by Epizyme outside China.
